We next wanted to investigate the signal requirements for anti-APO-1 and found that crosslinking of the APO-1 antigen is necessary for apoptosis to be induced. This is also supported by the fact that 4 -5 times less anti-APO-1 antibody is needed for induction of apoptosis when protein A as an Fc-binding crosslinker is mixed to the culture. In addition, anti-APO-1 immobilized on beads was perfectly capable of inducing apoptosis. This indicates that anti-APO-1 is not internalized for induction of apoptosis. These data suggest that the APO-1 antigen when triggered by the anti-APO-1 antibody delivers a signal which leads to the induction of the endogenous suicide process.
We also investigated the representation of the APO-1 antigen on normal cells and found that APO-1 is absent from the majority of resting T and B lymphocytes. However, after activation of T lymphocytes with PMA/PHA and Interleukin-2 the APO-1 antigen appears on the cell surface after about one day of activation. Only a slight additional increase of expression of APO-1 on the cell surface is observed on day 6 of activation. Day 1-and day 6-activated T cells, however, show a considerable difference in sensitivity for induction of apoptosis by anti-APO-1. Whereas hardly any apoptosis occurs on day 1-activated T cells, apoptosis is induced on day 6-activated T cells. Likewise, the majority of resting B cells is negative for APO-1 expression. B cells activated with pokeweed mitogen, however, express the AJPO-1 antigen and after incubation with the anti-APO-1 antibody cease to secrete IgM, probably due to induction of apoptosis. Apart from activated lymphocytes, the APO-1 antigen is expressed in a restricted fashion on a variety of normal tissues. Thus, as an example APO-1 is found in a basolateral distribition on epithelial cells of the colon mucosa. Interestingly, a number of colon carcinomas have lost APO-1 and others show a strong expression of APO-1.
Apart from the above cells, we tested a number of in vitro cell lines for the expression of APO-1 and the induction of apoptosis by anti-APO-1. We found that the human B cell lines SKW6.4, CESS, and BJAB were positive as well as the human T cell lines Jurkat, Molt, and CCRF-CEM. The human myeloid cell line U937, the gibbon T cell line MLA-144 and the mouse T cell line EL4 were negative. The cell lines of the above panel which express APO-1 also underwent apoptosis after incubation with anti-APO-1. The effects of anti-APO-1 in vitro prompted us to test whether the antibody was also effective in vivo. Although BJAB was the least anti-APO-1 sensitive of our in vitro B cell lines we selected this cell line for our in vivo experiments because it was the only line that grew to a large tumor in nu/nu mice. BJAB carries about 15*000 APO-1 antigens on the cell, surface. Approximately five weeks after injection of 5x10 7 BJAB cells into nu/nu mice BJAB tumors had reached a diameter of about 1 -2.5 cm. The tumor carrying animals were then injected once intravenously with 500 /xg of anti-APO-1 or a similar amount of isotype matched binding or non-binding control antibody, respectively. Experiments using radiolabeled antibodies indicated that anti-APO-1 and binding control antibodies localized in the tumor tissue while non-binding antibodies only showed background localization. Control antibodies did not have any effect on the BJAB tumors in the nu/nu mice. However, anti-APO-1 led to complete tumor regression in most animals between 5 and 14 days after injection of the antibody. Histological thin sections of tumors before complete regression showed that anti-APO-1 had also induced apoptosis in vivo.
In conclusion, therefore, our experiments showed that the APO-1 antigen is associated with growth and differentiation of human lymphocytes. The anti-APO-1 antibody induces growth inhibition and programmed cell death (apoptosis) of activated normal human lymphocytes and B and T cell tumors. Further experiments indicated that these processes can also be induced in a number of non-lymphoid tumors. The effect of anti-APO-1 is complement independent, and a transduction of the APO-1 mediated trans-membrane signal depends on efficient APO-1 crosslinking. Finally, a single intravenous injection of anti-APO-1 induces a rapid regression of a large tumor mass of the human Burkitt-like B cell lymphoma BJAB in nu/nu mice.
Future experiments are aimed at defining the physiological role of APO-1 and establishing a molecular understanding of growth inhibition and the mechanism of apoptosis. Furthermore, it is apparent that anti-APO-1 might be used as a diagnostic and putative therapeutic tool in oncology.
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